LeonaBio (LONA) Total Non-Current Liabilities (2019 - 2026)
LeonaBio (LONA) posted quarterly Total Non-Current Liabilities of $21.1 million for Q1 2026, down 66.54% quarter-over-quarter from $63.0 million in Q4 2025.
LeonaBio (LONA) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
LeonaBio (LONA) has reported Total Non-Current Liabilities for 3 consecutive years, with $21.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $21.1 million; the TTM figure through Mar 2026 stood at $21.1 million (changed N/A YoY), while the FY2025 annual figure was $63.0 million, changed N/A from the prior year.
- Total Non-Current Liabilities fell to $21.1 million in Q1 2026 per LONA's latest filing, from $63.0 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $63.0 million in Q4 2025 and bottomed at $21.1 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | LeonaBio | 180.91 Mn | 129.85 Mn | - | 22.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.07 Mn |
| Dec 31, 2025 | 62.96 Mn |
| Dec 31, 2019 | 3.86 Mn |